Natera, Inc. (NTRA)
Provides blood tests that detect cancer recurrence and screen for genetic disorders in pregnancies and inherited conditions.
$254.76-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+89.3%
The outlook
NTRA trades near $255 with strong analyst consensus backing it, with an average price target sitting roughly 11% above current levels. The stock is positioned well above both its 50- and 200-day moving averages and sits toward the upper end of its 52-week range, reflecting sustained upward momentum this year.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 21 analysts
Price trendAbove its 50- & 200-day averages
52-week range79% of the way from its 52-week low to high
Price targetAvg target +11% vs current price
Analyst price target
~12-month · 21 analysts$282.86average target+11.0% vs now
Now $254.76
Low $193.00High $330.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$36.48B
52-wk high
$288.04
52-wk low
$131.81
50-day avg
$239.29
200-day avg
$218.79
Trailing P/E
—